Patents by Inventor Shin Cheng Flournoy

Shin Cheng Flournoy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense inhibition of adam10 expression
    Publication number: 20030211610
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of ADAM10. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ADAM10. Methods of using these compounds for inhibition of ADAM10 expression and for treatment of diseases associated with expression of ADAM10 are provided.
    Type: Application
    Filed: December 17, 2002
    Publication date: November 13, 2003
    Inventors: Thomas P. Condon, Shin Cheng Flournoy
  • Antisense modulation of ADAM10 expression
    Patent number: 6228648
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ADAM10. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ADAM10. Methods of using these compounds for modulation of ADAM10 expression and for treatment of diseases associated with expression of ADAM10 are provided.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: May 8, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thomas P. Condon, Shin Cheng Flournoy
  • Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
    Patent number: 6180403
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-&agr;-converting enzyme (TACE). Antisense oligonucleotides targeted to nucleic acids encoding TACE are preferred. Methods of using these oligonucleotides for inhibition of TACE expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TACE or TNF-&agr; are provided.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: January 30, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Shin Cheng Flournoy, C. Frank Bennett
  • Enhanced antisense modulation of ICAM-1
    Patent number: 6111094
    Abstract: The present invention provides compositions and methods for detecting and modulating levels of intercellular adhesion molecule-1 (ICAM-1) proteins, including human ICAM-1.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: August 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Shin Cheng Flournoy
  • Antisense modulation of LFA-3
    Patent number: 6001651
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a nucleic acid encoding a lymphocyte function associated antigen 3 (LFA-3; also known as CD58) protein are provided.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: December 14, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Shin Cheng Flournoy, Jordan S. Pober, Weillie Ma
  • Antisense modulation of PECAM-1
    Patent number: 5955443
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a nucleic acid encoding a platelet endothelial cell adhesion molecule-1 (PECAM-1; also known as CD31 antigen or endoCAM) protein are provided.
    Type: Grant
    Filed: March 19, 1998
    Date of Patent: September 21, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Shin Cheng Flournoy, Hong Zhang